Enlivex Therapeutics Ltd.

Equities

ENLV

IL0011319527

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-17 pm EDT			5-day change	1st Jan Change
1.41 ^USD	+0.71%		-6.00%	-47.78%

Apr. 22	Enlivex Therapeutics Says First Two Patients Dosed in Knee Osteoarthritis Trial	MT
Apr. 22	Enlivex Therapeutics Ltd. Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra? in Patients with Knee Osteoarthritis	CI

Bioblast Pharma Ltd. and Enlivex Therapeutics Ltd. Announce Management Changes

November 19, 2018 at 04:15 pm EST

Bioblast Pharma Ltd. announced the execution of a definitive agreement to acquire Enlivex Therapeutics Ltd. Upon closing of the transaction, the combined company will change its name to Enlivex Therapeutics Ltd. It is expected that Mr. Shai Novik, current Executive Chairman of Enlivex will serve as the executive chairman of the combined company, Mr. Shmuel Hess, Ph.D., current CEO of Enlivex, will serve as the CEO of the combined company, and the board of directors of the combined company will include the current Enlivex board members.

Latest news about Enlivex Therapeutics Ltd.

Enlivex Therapeutics Says First Two Patients Dosed in Knee Osteoarthritis Trial	Apr. 22	MT
Enlivex Therapeutics Ltd. Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra? in Patients with Knee Osteoarthritis	Apr. 22	CI
Enlivex Therapeutics Receives Approval to Expand Trial of Allocetra to Treat Knee Osteoarthritis Into Denmark	Apr. 16	MT
Enlivex Therapeutics Ltd Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis	Apr. 16	CI
HC Wainwright Adjusts Enlivex Therapeutics Price Target to $7 From $12, Maintains Buy Rating	Apr. 12	MT
Sector Update: Health Care Stocks Softer Late Afternoon	Apr. 11	MT
Sector Update: Health Care	Apr. 11	MT
Enlivex Therapeutics Shares Fall After Topline Data from Sepsis Treatment Study	Apr. 11	MT
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra? in Patients with Sepsis	Apr. 11	CI
Tranche Update on Enlivex Therapeutics Ltd.'s Equity Buyback Plan announced on September 18, 2023.	Mar. 29	CI
Enlivex Therapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method	Feb. 07	CI
Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis	Jan. 17	CI
Enlivex Therapeutics Ltd.'s Equity Buyback Plan Extended till June 30, 2024.	Jan. 16	CI
Top Midday Gainers	Dec. 20	MT
Enlivex Therapeutics Ltd. Announces Completion of Enrollment of its Phase II Trial Evaluating Allocetra in Patients with Sepsis	Dec. 20	CI
Enlivex Therapeutics Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
HC Wainwright Cuts Enlivex Therapeutics Price Target to $12 From $15, Maintains Buy Rating	23-09-25	MT
Enlivex Therapeutics Ltd. announces an Equity Buyback for $1.5 million worth of its shares.	23-09-18	CI
Enlivex Therapeutics Ltd. Announces Addition to the Ongoing Phase II Trial of Allocetra in Patients with Sepsis, Initiates Clinical Program in Osteoarthritis	23-09-11	CI
Enlivex Therapeutics Ltd. Intends to Reduce its Workforce by Approximately 50%	23-09-11	CI
Enlivex Therapeutics Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-09-01	CI
Enlivex Therapeutics Ltd. authorizes a Buyback Plan.	23-08-29	CI
Enlivex Therapeutics Ltd. Announces Publication of Clinical and Exploratory Data from A Phase I/II Trials Evaluating Allocetra in Patients with COVID-19 United States	23-08-02	CI
Enlivex Therapeutics Ltd Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra? In Patients With Sepsis	23-07-31	CI

Chart Enlivex Therapeutics Ltd.

Duration

Period

More charts

Company Profile

Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.

Sector

Biotechnology & Medical Research

Calendar

2024-05-23 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.41 USD

Average target price

7 USD

Spread / Average Target

+396.45%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ENLIVEX THERAPEUTICS LTD.	-47.78%	26.52M
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
BIONTECH SE	-14.15%	21.84B
ARGENX SE	-1.05%	21.96B
GENMAB A/S	-5.29%	19.21B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
BEIGENE, LTD.	-4.16%	18.08B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B

Bio Therapeutic Drugs